Literature DB >> 26392104

Biomarker: Predictive or Prognostic?

Karla V Ballman1.   

Abstract

To demonstrate that a biomarker is predictive of treatment benefit, the study requires biomarker status on all patients as well as patients who were treated with the agent of interest and patients not so treated, preferably in the context of a randomized study. A formal statistical test of the treatment-by-biomarker interaction should be significant. To establish whether a marker is purely prognostic, it needs to be demonstrated that there is a significant association between the biomarker and outcome, regardless of treatment, and that treatment effects do not depend on the biomarker. Finally, a biomarker may have both predictive and prognostic implications. These concepts are summarized in Figure 2.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392104     DOI: 10.1200/JCO.2015.63.3651

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  122 in total

1.  Random forests of interaction trees for estimating individualized treatment effects in randomized trials.

Authors:  Xiaogang Su; Annette T Peña; Lei Liu; Richard A Levine
Journal:  Stat Med       Date:  2018-04-29       Impact factor: 2.373

2.  Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.

Authors:  Carlos H Barcenas; Akshara Raghavendra; Arup K Sinha; Masood Pasha Syed; Limin Hsu; Modesto G Patangan; Mariana Chavez-MacGregor; Yu Shen; Gabriel H Hortobagyi; Vicente Valero; Sharon H Giordano; Naoto T Ueno; Debu Tripathy
Journal:  Cancer       Date:  2017-02-15       Impact factor: 6.860

3.  Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?

Authors:  Giuseppe Saglio; Carmen Fava; Robert Peter Gale
Journal:  Haematologica       Date:  2019-05       Impact factor: 9.941

4.  Reply to Aron P. Kater et al.

Authors:  Riccardo Moia; Gianluca Gaidano; Davide Rossi
Journal:  Haematologica       Date:  2020-07       Impact factor: 9.941

5.  The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.

Authors:  Brianna Barsanti-Innes; Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Oncologist       Date:  2016-10-24

6.  How good are we at predicting the fate of someone with acute myeloid leukaemia?

Authors:  E Estey; R P Gale
Journal:  Leukemia       Date:  2017-03-17       Impact factor: 11.528

7.  Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Authors:  Peter K Kimani; Susan Todd; Lindsay A Renfro; Ekkehard Glimm; Josephine N Khan; John A Kairalla; Nigel Stallard
Journal:  Stat Med       Date:  2020-05-03       Impact factor: 2.373

Review 8.  Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research.

Authors:  Joshua J Meeks; Amir Goldkorn; Ana M Aparicio; David J McConkey
Journal:  Urol Oncol       Date:  2018-08-13       Impact factor: 3.498

9.  A transcriptional metabolic gene-set based prognostic signature is associated with clinical and mutational features in head and neck squamous cell carcinoma.

Authors:  Lu Xing; Mingzhu Guo; Xiaoqi Zhang; Xiaoqian Zhang; Feng Liu
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-17       Impact factor: 4.553

Review 10.  Biophysical technologies for understanding circulating tumor cell biology and metastasis.

Authors:  Derrick W Su; Jorge Nieva
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.